Finance

Lists
Q3 2026 earnings • released • EPS beat +7.77% • Revenue beat +2.95%
See results
GH:NASDAQ
Guardant Health Inc
$153.43
-8.99%
(-15.15) 1D
$142.07
-7.40% (-11.36)
Pre-market
Closed: Nov 5, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GH...
Open
$165.00
High
$165.10
Low
$151.92
Mkt. cap
20.59B
Avg. vol.
1.81M
Volume
24.61K
52-wk high
$191.01
52-wk low
$74.55
EPS
-$3.50
Beta
1.67
Shares outstanding
134.20M
No. of employees
2K
Open
$165.00
High
$165.10
Low
$151.92
Mkt. cap
20.59B
Avg. vol.
1.81M
Volume
24.61K
52-wk high
$191.01
52-wk low
$74.55
EPS
-$3.50
Beta
1.67
Shares outstanding
134.20M
No. of employees
2K
News stories
From web sources and news partners
Profile
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. Wikipedia
About Guardant Health Inc
CEOHelmy Eltoukhy | AmirAli Talasaz
Employees2.5K
Founded2012
HeadquartersPalo Alto, California, United States
SectorHealth Care
IndustryHealth care provider
Websiteguardanthealth.com
Analyst ratings
Based on 14 analysts giving stock ratings to GH in the past 3 months
Strong buy
Buy
14
Hold
0
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for GH in the last 3 months.
Highest
Current $153.43
$225.00 (+46.65%)
Average
$206.75 (+34.75%)
Lowest
$193.00 (+25.79%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luke Sergott
Barclays
Buy
Maintained
$220.00
+43.4%
11/06/2026
Mark Massaro
BTIG
Buy
Maintained
$210.00
+36.9%
10/27/2026
Max Masucci
Roth MKM
Buy
Initiated
$200.00
+30.4%
10/22/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
$200.00
+30.4%
10/20/2026
Eve Burstein
Bernstein
Buy
Reiterated
$210.00
+36.9%
10/19/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
$195.00
+27.1%
10/14/2026
Lu Li
Bank of America Securities
Buy
Maintained
$200.00
+30.4%
10/09/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
$200.00
+30.4%
10/09/2026
Subbu Nambi
Guggenheim
Buy
Maintained
$200.00
+30.4%
10/01/2026
Evie Koslosky
Goldman Sachs
Buy
Maintained
$225.00
+46.6%
09/20/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
09/15/2026
David Westenberg
Piper Sandler
Buy
Maintained
$193.00
+25.8%
09/15/2026
Unknown Analyst
UBS
Buy
Maintained
$225.00
+46.6%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
$225.00
+46.6%
09/09/2026
Jamie Clark
Rothschild & Co Redburn
Buy
Initiated
$203.00
+32.3%
09/08/2026
Matt Larew
William Blair
Buy
Maintained
-
-
09/08/2026
Bradley Bowers
Mizuho Securities
Buy
Maintained
$200.00
+30.4%
08/04/2026
Mason Carrico
Stephens
Buy
Maintained
$195.00
+27.1%
08/04/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Maintained
$205.00
+33.6%
08/02/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
$180.00
+17.3%
08/03/2026
Dan Leonard
RBC Capital
Buy
Reiterated
$200.00
+30.4%
07/31/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
$210.00
+36.9%
07/31/2026
Brandon Couillard
Wells Fargo
Buy
Maintained
$125.00
-18.5%
07/29/2026
Patrick B Donnelly
Citi
Buy
Maintained
$215.00
+40.1%
07/08/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
$200.00
+30.4%
07/06/2026
Puneet Souda
Leerink Partners
Buy
Reiterated
-
-
06/02/2026
Paige Chamberlain‏
Wolfe Research
Buy
Reiterated
$150.00
-2.2%
06/01/2026
Unknown Analyst
Wolfe Research
Buy
Reiterated
$150.00
-2.2%
06/01/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
05/27/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$129.00
-15.9%
05/08/2026
Andrew Cooper
Raymond James
Buy
Reiterated
$129.00
-15.9%
02/23/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$0.29 / -$0.31
+7.77%beat
Revenue / Est. (USD)
360.98M / 350.64M
+2.95%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
265.20M
281.27M
301.66M
334.98M
Cost of goods sold
93.59M
99.49M
104.92M
115.95M
Cost of revenue
93.59M
99.49M
104.92M
115.95M
Research and development expenses
89.96M
98.26M
91.04M
96.53M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
180.53M
204.20M
227.06M
250.61M
Operating expense
270.48M
302.46M
318.10M
347.15M
Total operating expenses
364.07M
401.96M
423.02M
463.10M
Operating income
-98.87M
-120.69M
-121.35M
-128.12M
Other non operating income
-48.00K
-4.69M
1.55M
308.00K
EBT including unusual items
-92.59M
-130.22M
-111.70M
-119.96M
EBT excluding unusual items
-92.47M
-116.52M
-111.70M
-118.96M
Income tax expense
136.00K
-1.73M
372.00K
185.00K
Effective tax rate
-0.15%
1.33%
-0.33%
-0.15%
Other operating expenses
-
-
-
-
Net income
-92.72M
-128.49M
-112.08M
-120.14M
Net profit margin
-34.96%
-45.68%
-37.15%
-35.87%
Earnings per share
-0.39
-0.50
-0.45
-0.42
Interest and investment income
7.39M
10.03M
11.15M
10.20M
Interest expense
-943.00K
-1.18M
-3.05M
-1.35M
Net interest expenses
6.45M
8.85M
8.10M
8.85M
Depreciation and amortization charges
-
-
-
-
EBITDA
-89.47M
-110.64M
-111.91M
-118.56M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps